COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
E+S Rück expects demand for high-quality reinsurance protection to remain strong in the German market
E+S Rück expects strong demand for high-quality reinsurance protection in the German market amid increasing risks and competition. Market environment stable with growing capacities and intensifying competition -
COMMUNIQUÉ DE PRESSE
OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer
OSE Immunotherapeutics reports positive results from Combi-TED Phase 2 trial with Tedopi® in metastatic NSCLC. Study to be presented at ESMO 2026. KOL webcast scheduled -
COMMUNIQUÉ DE PRESSE
OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 randomisée Combi-TED de Tedopi® (OSE2101) dans le cancer du poumon non à petites cellules métastatique
OSE Immunotherapeutics annonce des résultats positifs de l'étude de Phase 2 Combi-TED de Tedopi dans le cancer du poumon non à petites cellules métastatique, présentés au congrès annuel de l'ESMO. Webcast prévu avec des experts internationaux -
-
-
-
-
COMMUNIQUÉ DE PRESSE
DKSH to Establish a Healthcare Platform in the Middle East and Scale Up Capabilities With the Acquisition of NewBridge Pharmaceuticals
DKSH Management Ltd. to establish a healthcare platform in the Middle East and North Africa (MENA) by acquiring NewBridge Pharmaceuticals for USD 390 million. The acquisition expands DKSH's healthcare capabilities and geographic footprint
